usdaed

They announced recalls this week. Nearly 2.4 million vehicles. Rearview cameras, windshield wipers… the usual suspects. Honestly, it’s like they’re actively trying to give me a reason to diversify. The National Highway Traffic Safety Administration is having a field day, I suspect. And it’s not exactly a new problem. Remember last month? 4.3 million vehicles for towing-trailer lights and brakes. They’re trying to fix some of it with software updates, which is… clever, I guess. But it still chips away at the margins, and, more importantly, the reputation. Investors don’t like surprises, and constant recalls are basically a flashing neon sign screaming ‘potential problem’.

This CoreWeave, sprung forth from the initial public offering not long ago, has enjoyed a period of accelerated growth. Yet, beneath the surface of these reported gains lurks a disquieting imbalance. Capital expenditure, a relentless outward flow of resources, and the specter of an artificial intelligence ‘bubble’ – a term freighted with the memory of past enthusiasms and subsequent collapses – have cast a pall over its prospects. The predictable consequence was a ‘panic button’ response, a flinching from the reality of unsustainable expansion.

Ninety-nine percent growth for Mounjaro? A 175% jump for Zepbound? Numbers don’t lie, but they sure as hell can mislead. Lilly’s got the GLP-1 game LOCKED DOWN… for now. The question isn’t if the bubble will burst, it’s when, and how spectacularly. And nobody, absolutely NOBODY, seems to be bracing for impact.

I can’t offer you a crystal ball (they’re notoriously unreliable, and the warranty is usually voided by the first paradox), but I can point you towards three companies currently exhibiting characteristics that might—and I stress might—lead to significant returns over the next decade. Each one, at the time of writing, appears to be doing things that aren’t actively self-destructive, which, in the grand scheme of things, is a surprisingly rare quality.

A slight dip in Nvidia’s valuation following their recent pronouncements? How very…human. It provides a perfectly reasonable entry point, of course. The company continues to amass revenue at a frankly alarming rate – a 73% surge in the last quarter, if you please. One almost feels obliged to applaud.

They clocked a 51% earnings jump last year, hitting $10.65 a share. A 36% revenue spike. Impressive, sure. But it’s the how that’s interesting. Pricing power, baby. They’re not just building chips; they’re dictating terms. 72% of the pure-play foundry market? That’s not a market share, that’s a stranglehold. And they’re expanding into Foundry 2.0 – packaging, testing, the whole shebang. They’re at 39% of that market now, six points up from last year, while the competition is… sputtering. Six percent. That’s not a competitor, that’s a rounding error.

The price? Around $78.86 a share. Which, if you’re keeping score, isn’t bad. Not bad at all. It’s the kind of money that makes you question all your life choices, frankly. Like, should I have gone to law school? Should I have invested in beanie babies? The possibilities are endless, and equally depressing.

But hope, as they say, springs eternal – or at least until the next quarterly report. Novo Nordisk, with a subtlety worthy of a seasoned gambler, has quietly released data from a Phase 2 study of another candidate, UBT251. A curious substance, this – a veritable cocktail of gut hormones designed to trick the body into believing it’s already had a substantial meal. Ingenious, really, if you ignore the ethical implications. And in the world of pharmaceutical innovation, ethics are often a secondary consideration.